Antengene Corporation Limited (HK:6996) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Antengene Corporation Limited has announced that the Malaysian National Pharmaceutical Regulatory Agency approved a New Drug Application for XPOVIO® for two new indications in the treatment of multiple myeloma. This milestone reflects the company’s commitment to expanding its oncology portfolio and the potential for XPOVIO® to offer novel treatment options for patients. The company advises shareholders and potential investors to exercise caution when dealing in its shares.
For further insights into HK:6996 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue